It would be very interesting to see whether Lilly’s share price will rise along with the marketing of Mounjaro. After all, the clinical research of this drug cost USD2.8 billion.
article from Cartkoo.com/weight-loss-updates
Recently, The New England Journal of Medicine published the result of the “SURMOUNT-1” study on the efficacy and safety of GLP-1/GIP dual-channel receptor agonist Tirzepatide. The study is for obese or overweight adults without diabetes. The study finds that different doses (5 mg , 10mg, 15mg) Tirzepatide can significantly and continuously reduce the weight of obese patients. The highest dose group lost an average of 48 pounds in 72 weeks.
Weight loss by dose group during a 72-week period:
➤ 5mg group: weight loss of 16.1kg, ( 95%CI , −16.8 to −15.2)
➤ 10mg group: weight loss of 22.2 kg, ( 95%CI , −22.2 to −20.6)
➤ 15mg group: weight loss of 23.6 kg, ( 95%CI , −23.3 to −21.7)
➤Placebo group: weight loss of 2.4 kg, ( 95% CI , −3.2 to −1.6).
The study has been done long before Mounjaro (tirzepatide), developed by Eli Lilly, was approved by the U.S. FDA to improve glycemic control in adults with type 2 diabetes. Mounjaro is the first dual agonist for the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Mounjaro is administered through subcutaneous injection on weekly basis. The study shows that flexibility in dosing is feasible, and can be adjusted according to tolerability of testing targets. According to the SURPASS part of the clinical study, the highest dose (15mg) can reduce the value of glycated hemoglobin HbA1C by a significant 1.6%, comparing with placebo group.
Besides the hypoglycemic effect, the SURMOUNT-1 study on obese patients without diabetes showed that the highest dose (15mg) can significantly reduce the patient’s body weight by an average of 22.5% (24 kg), which means that Mounjaro (tirzepatide) is currently the only potential weight loss medication that comes with the ability to reduce more than 20% of body weight. The data indicates that Mounjaro (tirzepatide) might become the most successful weight loss medication in history.
WEIGHT LOSS MECHANISM:
Lower appetite and reduce energy intake through higher satiety and thus realize lowering food consumption. It’s very interesting to see how much the fat mass loss accounts for the phenomenal weight loss. Compared with the semaglutide group, a competiting medication with similar clinical outcome, Tirzepatide significantly reduces the fat mass of the patients. The percentage of fat mass in overall weight loss mass was higher than that of semaglutides.
➤ The most common adverse effects were gastrointestinal (nausea, diarrhea, and constipation), most of which were mild to moderate.
➤ Four confirmed cases of pancreatitis were reported, evenly distributed among treated and placebo groups.
➤ The incidence of cholelithiasis was similar between the two groups compared with the placebo group. Cholecystitis and acute cholecystitis were reported with a higher incidence rate in the treated group, while the overall incidence rate was low (≤ 0.6%)